Golden State Equity Partners Bristol Myers Squibb CO Transaction History

Golden State Equity Partners

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 20, 2023	BUY	$57.89 - $64.73 $627,469 - $701,608	10,839 Added 461.43%	13,188 $765,000
Q2 2023 Jul 19, 2023	SELL	$63.71 - $70.74 $334,413 - $371,314	-5,249 Reduced 69.08%	2,349 $150,000
Q1 2023 Jun 01, 2023	SELL	$65.71 - $74.53 $789,374 - $895,328	-12,013 Reduced 61.26%	7,598 $527 Million
Q1 2022 May 18, 2022	BUY	$61.48 - $73.72 $262,642 - $314,931	4,272 Added 27.85%	19,611 $1.43 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $530,449 - $636,056	8,628 Added 128.57%	15,339 $968,000
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $21,881 - $25,508	408 Added 6.47%	6,711 $418,000
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $688,738 - $806,768	-11,640 Reduced 64.87%	6,303 $373,000
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $161,213 - $175,561	2,604 Added 16.98%	17,943 $1.2 Million
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $910,216 - $1.02 Million	15,339 New	15,339 $968,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

Stay updated on Golden State Equity Partners with notifications on news.